MSTX


Company Update (NYSEMKT:MSTX): Mast Therapeutics Inc Announces Presentation Of Results Of Nonclinical Study Of Vepoloxamer In Chronic Heart Failure At The HFSA’s

Mast Therapeutics Inc (NYSEMKT:MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle …

Company Update (NYSE MKT:MSTX): Mast Therapeutics Inc to Host Analyst & Investor Day

Mast Therapeutics Inc (NYSEMKT:MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle …

Roth Capital Shines Light on Mast Therapeutics Inc Following Meeting with Key Opinion Leader

Roth Capital’s healthcare analyst Michael Higgins weighed in with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), after hosting an investor meeting with a Key Opinion …

Roth Capital Weighs In on Mast Therapeutics Inc Ahead of 4th Annual Sickle Cell Disease Conference

Roth Capital’s healthcare analyst Michael Higgins weighed in today with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), ahead of the 4th Annual Sickle …

Cowen Maintains Outperform on Mast Therapeutics Inc Ahead of Sickle Cell Crisis EPIC Data in 1Q:16

In a research report issued today, Cowen analyst Ritu Baral maintained an Outperform rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), while no price …

Roth Capital Reiterates Buy on Mast Therapeutics Inc Following 2Q:15 Update

In a research report issued today, Roth Capital analyst Michael Higgins reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) with a …

Canaccord Reiterates Buy on Mast Therapeutics Inc (MSTX) Ahead of Top-line Phase 3 Sickle Cell Data

In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) with a $3.00 …

Roth Capital Maintains Buy on Mast Therapeutics Inc (MSTX) Following Initiation of EPIC-E Study

Roth Capital’s healthcare analyst Michael Higgins came out with a research report on Mast Therapeutics Inc (NYSEMKT:MSTX), after the company announced the initiation of enrollment into …

Canaccord Reiterates Buy On Mast Therapeutics In Light Of Recent Preclinical Data In Embolic Stroke

Canaccord Genuity’s healthcare analyst John Newman weighed in today with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), as the company recently announced that, in a …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts